Tusk Therapeutics is a privately-held immuno-oncology company that has established a pipeline of antibodies against novel and validated targets in the immune response to cancer. Their programmes target the tumour microenvironment and modulate, activate, or deplete immune cells. Tusk has a world-class leadership team and scientific advisors, with extensive experience in antibody discovery and drug development. The company is based in Stevenage, UK and is focused on developing novel immune modulating therapeutics based on an in-depth understanding of the innate immune system, with a special focus on Natural Killer (NK) cell biology, to help cancer patients achieve full recovery.